Cadrenal Therapeutics, Inc. Foreign Income Tax Expense (Benefit), Continuing Operations
Cadrenal Therapeutics, Inc. (CVKD) reported Foreign Income Tax Expense (Benefit), Continuing Operations of -$1.75 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2024-03-11
- Cadrenal Therapeutics, Inc. foreign income tax expense (benefit), continuing operations for fiscal 2023 was -$1.75M.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 11 month | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|---|
| 2023-12-31 | -$1.75M 10-K · filed 2024-03-11 | |
| 2022-12-31 | -$1.41M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |